Tags: NICE\darzalez\lenalidomideDarzalexEuropean Commission
| Profile | Contacts | Recent Articles on Subject | |
|---|---|---|---|
| 1 | 1387865 PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom | NICE nod for Darzalex with lenalidomide and dexamethasone - about 1 year ago | |
| 2 | Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland | Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 8 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 12 months ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago TAK-279 Demonstrates Improvements in ACR 20 Response for Psoriatic Arthritis - about 1 year ago | |
| 3 | Amir Ali, PharmD, BCOP Pharmacy Times Clinical Hem/Onc Pharmacist. USC Assistant Professor. Founder of OncologySolutionsRx. Los Angeles, CA | Impact of SC Daratumumab - 21 days ago | |
| 4 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | ||
| 5 | Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA | ||
| 6 | Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York | ||
| 7 | PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom | MHRA approves Astellas’ Vyloy combination for gastric cancer - 3 months ago | |
| 8 | Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey | ||
| 9 | Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. | Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 4 months ago New Data on TYK2 Inhibitors for Psoriasis, Psoriatic Arthritis - 12 months ago | |
| 10 | Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey | FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 7 months ago |